Ceftolozane / tazobactam (new indication: bacterial infections; patients aged < 18 years (antibiotic of last resort))

Subject:

• Active Sustance: Ceftolozance / tazobactam
• Name: Zerbaxa®
• Therapeutic area: Bacterial infections
• Pharmaceutical company: MSD Sharp & Dohme GmbH

Time table:

• Start: 15.08.2022
• Final decision by G-BA: 02.02.2023

Final decision:

• Additional benefit proven